Seminars in Oncology
Volume 30, Issue 5 , Pages 689-697 , October 2003

The development of differentiation agents for the treatment of prostate cancer

  • Matt Galsky

      Affiliations

    • Department of Medicine, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY, USA
    • ,
  • W.Kevin Kelly

      Affiliations

    • Genitourinary Oncology Service, Division of Solid Tumor, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • Corresponding Author InformationAddress reprint requests to W. Kevin Kelly, DO, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA

References 

  1. Huang ME, Ye YC, Chen SR, et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567–572
  2. Scher HI, Heller G. Clinical states in prostate cancer (Toward a dynamic model of disease progression). Urology. 2000;55:323–327
  3. LaTulippe E, Satagopan J, Smith A, et al.  Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 2002;62:4499–4506
  4. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer. 2001;1:181–193
  5. Kelloff GJ, Lieberman R, Steele VE, et al.  Chemoprevention of prostate cancer (Concepts and strategies). Eur Urol. 1999;35:342–350
  6. Feldman D, Zhao XY, Krishnan AV. Vitamin D and prostate cancer. Endocrinology. 2000;141:5–9
  7. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev. 2001;81:1269–1304
  8. Tallman MS, Andersen JW, Schiffer CA, et al.  All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021–1028
  9. Meyskens FL, Surwit E, Moon TE, et al.  Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid (A randomized trial). J Natl Cancer Inst. 1994;86:539–543
  10. Hong WK, Lippman SM, Itri LM, et al.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990;323:795–801
  11. Peck GL. Topical tretinoin in actinic keratosis and basal cell carcinoma. J Am Acad Dermatol. 1986;15:829–835
  12. Reichman ME, Hayes RB, Ziegler RG, et al.  Serum vitamin A and subsequent development of prostate cancer in the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Cancer Res. 1990;50:2311–2315
  13. Dahiya R, Park HD, Cusick J, et al.  Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int J Cancer. 1994;59:126–132
  14. Pollard M, Luckert PH, Sporn MB. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4- hydroxyphenyl)retinamide. Cancer Res. 1991;51:3610–3611
  15. Pienta KJ, Nguyen NM, Lehr JE. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res. 1993;53:224–226
  16. Kelly WK, Osman I, Reuter VE, et al.  The development of biologic end points in patients treated with differentiation agents (An experience of retinoids in prostate cancer). Clin Cancer Res. 2000;6:838–846
  17. Trump DL, Smith DC, Stiff D, et al.  A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer (A clinical trial with detailed pharmacokinetic analysis). Cancer Chemother Pharmacol. 1997;39:349–356
  18. Culine S, Kramar A, Droz JP, et al.  Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer. J Urol. 1999;161:173–175
  19. Muindi JR, Young CW, Warrell RP. Clinical pharmacology of all-trans retinoic acid. Leukemia. 1994;8:1807–1812
  20. Muindi J, Frankel SR, Miller WH, et al.  Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations (Implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia). Blood. 1992;79:299–303
  21. Rigas JR, Francis PA, Muindi JR, et al.  Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. J Natl Cancer Inst. 1993;85:1921–1926
  22. Adedoyin A, Stiff DD, Smith DC, et al.  All-trans-retinoic acid modulation of drug-metabolizing enzyme activities (Investigation with selective metabolic drug probes). Cancer Chemother Pharmacol. 1998;41:133–139
  23. Jung LL, Zamboni WC, Frye RF, et al.  Modulation of all-trans-retinoic acid (ATRA) disposition with ketoconazole and disulfiram in patients with hormone-refractory prostate cancer. Proc Am Soc Clin Oncol. 2001;20:112a; (abstr 446)
  24. Liarozole Study Group Debruyne FJ, Murray R, Fradet Y, et al.  Liarozole—A novel treatment approach for advanced prostate cancer (Results of a large randomized trial versus cyproterone acetate). Urology. 1998;52:72–81
  25. Majewski S, Szmurlo A, Marczak M, et al.  Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis (Anti-angiogenic effect on HPV-harboring tumor-cell lines). Int J Cancer. 1994;57:81–85
  26. Smith MA, Parkinson DR, Cheson BD, et al.  Retinoids in cancer therapy. J Clin Oncol. 1992;10:839–864
  27. Shalev M, Thompson TC, Frolov A, et al.  Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy. Clin Cancer Res. 2000;6:3845–3849
  28. Ferrari AC, Stone N, Stock R, et al.  13-Cis retinoic acid and complete androgen blockade in advanced hormone-naive prostate cancer patients (Report of a phase II randomized study). J Clin Oncol. 2002;20:538–544
  29. DiPaola RS, Weiss RE, Cummings KB, et al.  Effect of 13-cis-retinoic acid and alpha-interferon on transforming growth factor beta1 in patients with rising prostate-specific antigen. Clin Cancer Res. 1997;3:1999–2004
  30. Goodin S, Rafi M, Cohen S, et al.  A phase II trial of 13-cis-retinoic acid, alpha-interferon, and paclitaxel in patients with advanced prostate cancer. Proc Am Soc Clin Oncol. 2000;19:359a; (abstr)
  31. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res. 1990;10:1307–1311
  32. Corder EH, Guess HA, Hulka BS, et al.  Vitamin D and prostate cancer (A prediagnostic study with stored sera). Cancer Epidemiol Biomarkers Prev. 1993;2:467–472
  33. Osborn JL, Schwartz GG, Smith DC, et al.  Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol. 1995;1:195–198
  34. Gross C, Stamey T, Hancock S, et al.  Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol. 1998;159:2035–2039
  35. Trump DL, Serafine S, Brufsky A, et al.  High dose calcitriol (1,25(OH)2 vitamin D3) + dexamethasone in androgen independent prostate cancer. Proc Am Soc Clin Oncol. 2000;19:337a; (abstr 1327)
  36. Solit DB, Smaletz O, DeLaCruz A, et al.  Phase I study of high dose calcitriol (1.25(OH)2) vitamin D3) and zoledronic acid in patients with prostate cancer. Proc Am Soc Clin Oncol. 2002;21:195a; (abstr 777)
  37. Liu G, Oettel K, Ripple G, et al.  Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. Clin Cancer Res. 2002;8:2820–2827
  38. Hershberger PA, Yu WD, Modzelewski RA, et al.  Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel- induced apoptosis. Clin Cancer Res. 2001;7:1043–1051
  39. Berman CL, Glode M, Crawford ED, et al.  Vitamin D, dexamethasone, and carboplatin for hormone refractory prostate cancer, a phase II study. Proc Am Soc Clin Oncol. 2002;21:160b; (abstr 2455)
  40. Beer TM, Eilers KM, Garzotto M, et al.  Weekly high-dose calcitriol and docetaxel in metastatic androgen- independent prostate cancer. J Clin Oncol. 2003;21:123–128
  41. Marks P, Rifkind RA, Richon VM, et al.  Histone deacetylases and cancer (Causes and therapies). Nat Rev Cancer. 2001;1:194–202
  42. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors (Inducers of differentiation or apoptosis of transformed cells). J Natl Cancer Inst. 2000;92:1210–1216
  43. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 1996;5:245–253
  44. Archer SY, Meng S, Shei A, et al.  p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA. 1998;95:6791–6796
  45. Butler LM, Agus DB, Scher HI, et al.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000;60:5165–5170
  46. Butler LM, Webb Y, Agus DB, et al.  Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res. 2001;7:962–970
  47. Sandor V, Robbins AR, Robey R, et al.  FR901228 causes mitotic arrest but does not alter microtubule polymerization. Anticancer Drugs. 2000;11:445–454
  48. Walls R, Thibault A, Liu L, et al.  The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells. Prostate. 1996;29:177–182
  49. Gilbert J, Baker SD, Bowling MK, et al.  A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res. 2001;7:2292–2300
  50. Kelly WK, Richon VM, Troso-Sandoval T, et al.  Suberoylanilide hydoxamic acid (SAHA), a histone deacetylase inhibitor (Biologic activity without toxicity). Proc Am Soc Clin Oncol. 2001;20:87a; (abstr 344)
  51. Kelly WK, O’Connor O, Richon VM, et al.  Phase I clinical trial of an oral formulation of the histone deacetylase inhibitor (Suberoylanilide hydroxamic acid (SAHA)). Fourteenth EORTC-NCI-AACR Symposium on Molecular Targets and Cancer, Frankfurt, Germany, November 19–22 2002;
  52. Gilbert J, Baker SD, Donehower RC, et al.  Methyltransferase (MT) activity and gene expression in tumor biopsies from patients enrolled in a phase I study of the MT inhibitor, 5-azacytidine, and the histone deacetylase inhibitor, phenylbutyrate, in refractory solid tumors. Proc Am Soc Clin Oncol. 2001;20:87a; (abstr 344)
  53. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid- activated transcription factor. Cell. 1994;79:1147–1156
  54. Sarraf P, Mueller E, Jones D, et al.  Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med. 1998;4:1046–1052
  55. Mueller E, Smith M, Sarraf P, et al.  Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA. 2000;97:10990–10995
  56. Kroll TG, Sarraf P, Pecciarini L, et al.  PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science. 2000;289:1357–1360
  57. Kubota T, Koshizuka K, Williamson EA, et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998;58:3344–3352
  58. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design (Application to cytostatic antineoplastic agents). J Clin Oncol. 2002;20:4478–4484
  59. Scher HI, Heller G. Picking the winners in a sea of plenty. Clin Cancer Res. 2002;8:400–404
  60. Bowling MK, Nelson JB, Tong KP, et al.  Biomarker responses in men with advanced prostate cancer (PCA) to infusional phenylbutyrate (PB). Proc Am Soc Clin Oncol. 1996;15:94; (abstr 43)
  61. Urban D, Myers R, Manne U, et al.  Evaluation of biomarker modulation by fenretinide in prostate cancer patients. Eur Urol. 1999;35:429–438
  62. Lotan Y, Xu XC, Shalev M, et al.  Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol. 2000;18:116–121

PII: S0093-7754(03)00355-5

doi: 10.1016/S0093-7754(03)00355-5

Seminars in Oncology
Volume 30, Issue 5 , Pages 689-697 , October 2003

Article Tools

* Image Usage & Resolution